Monday, February 6, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Antimicrobial Resistance

Antibiotics Update: Three Discovery Projects That You Should Know About

by Global Biodefense Staff
July 12, 2017

Superbugs & Superdrugs 2017Supported by BARDA, CARB-X and big pharma, Superbugs & Superdrugs USA will provide insight into both traditional and non-traditional approaches towards combatting AMR whilst looking at financing initiatives and keeping attendees at the forefront of clinical breakthroughs.

Understanding the translational link between animals and humans; navigating the pitfalls of early drug discovery; and evaluating the potential of immunotherapies will be a major focus, as will hearing from a selection of biotech and pharma companies currently undertaking clinical research. This will include case studies from Pfizer, MedImmune, Merck, Visterra and ContraFect.

Event highlights will include a keynote presentation by Tim Opperman, Senior Research Scientist from Microbiotix.

The talk will discuss advances in the three-prong approach taken by Microbiotix to address the problem of MDR Gram-negative pathogens. It is claimed that all three discovery projects have demonstrated efficacy in murine models of infection.

Project 1 Virulance -Funded by CARB-X: Attendees will hear how a novel phenoxyacetamide series exhibits potent activity against type 3 secretion in Pseudomonas aeruginosa by targeting the assembled needle protein PscF.

Project 2 Intrinsic Resistance: Microbiotix will explain how novel pyranopyridine inhibitors of RND-type efflux pump inhibitors exhibit broad spectrum activity against pathogens of the Enterobacteriaceae and favourable pharmacokinetics in mice.

Project 3 Novel Essential Target: The talk will explore how a series of novel oxadiazoles bind to a unique site on the ribosome, resulting in potent inhibition of the essential non-stop ribosome rescue pathway in Gram-positive and negative pathogens, including MDR Neisseria gonorrhoeae and Francisella tularensis. These compounds exhibited potent antibacterial activity and oral bioavailability.

A full speaker line-up and detailed agenda is available at www.superbugs-usa.com/globalbiodefence

Superbugs & Superdrug’s USA will take place on 13th and 14th November at the Renaissance Woodbridge Hotel in Iselin, New Jersey.

Tags: AntimicrobialsASPREventsHHS

Related Posts

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC